PLEASANTON, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, said today that it will be participating in the 24th Annual JP Morgan Healthcare Conference on Thursday, January 12.
D. Keith Grossman, president and chief executive officer, will provide an update on the company, beginning at 9 a.m., Pacific Standard Time (12 p.m. Eastern Standard Time).
The presentation will be available through the conference web site at http://equityconferences.jpmorgan.com or on the company’s web site, http://www.thoratec.com .
Thoratec Corporation is a world leader in hemodyanmic restoration therapy -- developing products to treat cardiovascular disease. The company’s product line includes the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (left ventricular assist system) with nearly 10,000 devices implanted in patients suffering from heart failure. Thoratec’s HeartMate LVAS is the first and, to date, only FDA-approved device for Destination Therapy, or the permanent support of late-stage heart failure patients who are not eligible for heart transplantation. Thoratec’s product line also includes the Vectra(R) vascular access graft (VAG) for patients undergoing hemodialysis. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web sites at http://www.thoratec.com or http://www.itcmed.com .
Thoratec Corporation
CONTACT: investors, Cynthia Lucchese, Senior Vice President, ChiefFinancial Officer of Thoratec Corporation, +1-925-847-8600; or Neal Rosenof Kalt Rosen & Co., +1-415-397-2686, for Thoratec Corporation; or media,Jennifer Chan of FischerHealth, Inc., +1-310-577-7870, ext. 164, orjchan@fischerhealth.com, for Thoratec Corporation
